Iguratimod (IGU) is a novel small-molecule anti-rheumatic drug with remarkable effectiveness and good safety for the treatment of active rheumatoid arthritis. Its mechanism of action is related to its ability to act simultaneously on T and B lymphocytes. IGU can effectively inhibit expression of various inflammatory factors, inhibit B cells from producing immunoglobulins and autoantibodies, downregulate T-cell-mediated cellular immunity, accelerate bone formation, and exert some activity against anti-pulmonary fibrosis. In recent years, IGU has been gradually applied to the treatment of a variety of rheumatic diseases, such as Sjögren's syndrome, ankylosing spondylitis and systemic lupus erythematosus. This article reviews the mechanism of action and clinical research status of IGU, and provides reference for future research on its mechanism of action and clinical application.

中文翻译：

---

伊古拉莫德的分子机制和临床应用：综述。

依古拉莫德（IGU）是一种新型的小分子抗风湿药，在治疗活动性类风湿关节炎方面具有显着的疗效和良好的安全性。其作用机制与其同时作用于T和B淋巴细胞的能力有关。IGU可有效抑制各种炎症因子的表达，抑制B细胞产生免疫球蛋白和自身抗体，下调T细胞介导的细胞免疫力，加速骨骼形成，并发挥某些抗肺纤维化的活性。近年来，IGU已逐渐应用于各种风湿性疾病的治疗，例如干燥综合征，强直性脊柱炎和系统性红斑狼疮。本文综述了IGU的作用机理和临床研究现状，